Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno Royer

Showing results (71-80 of 107) with videos related to

Pageof 11
Sort By:
Journal of Cancer|March 26, 2014
Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in ConsolidationGuillemette Fouquet, Benjamin Hebraud, Sylvain Garciaz, et al.
Cancer Medicine|March 15, 2025
Real-World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated Before the Era of Anti-CD38 Antibodies: The EMMY Cohort From 2017 to 2020Laure Vincent, Olivier Decaux, Aurore Perrot, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 17, 2025
The Impact of Anti-CD38 Monoclonal Antibodies in Frontline Therapy for Patients With Newly Diagnosed Multiple Myeloma: Real-Life Results From the EMMY StudyThomas Chalopin, Olivier Decaux, Cyrille Hulin, et al.
British Journal of Haematology|March 28, 2023
Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myelomaLaurent Garderet, Frederique Kuhnowski, Benoit Berge, et al.
Blood|August 12, 2011
Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use programMehdi Khellaf, Marc Michel, Philippe Quittet, et al.
Leukemia|September 15, 2025
Molecular profiling and risk stratification in solitary bone plasmacytomaBarbara Burroni, Stéphanie Harel, Raphaele Seror, et al.
Blood|September 3, 2021
Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experienceAlexis Caulier, Murielle Roussel, Pierre Morel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2019
Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple MyelomaAurore Perrot, Valérie Lauwers-Cances, Elodie Tournay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2016
Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST TrialCyrille Hulin, Andrew Belch, Chaim Shustik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2013
The translocation t(4;14) can be present only in minor subclones in multiple myelomaBenjamin Hébraud, Denis Caillot, Jill Corre, et al.
Pageof 11

Showing results (71-80 of 107) with videos related to

Sort By:
Pageof 11
Journal of Cancer|March 26, 2014
Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in ConsolidationGuillemette Fouquet, Benjamin Hebraud, Sylvain Garciaz, et al.
Cancer Medicine|March 15, 2025
Real-World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated Before the Era of Anti-CD38 Antibodies: The EMMY Cohort From 2017 to 2020Laure Vincent, Olivier Decaux, Aurore Perrot, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 17, 2025
The Impact of Anti-CD38 Monoclonal Antibodies in Frontline Therapy for Patients With Newly Diagnosed Multiple Myeloma: Real-Life Results From the EMMY StudyThomas Chalopin, Olivier Decaux, Cyrille Hulin, et al.
British Journal of Haematology|March 28, 2023
Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myelomaLaurent Garderet, Frederique Kuhnowski, Benoit Berge, et al.
Blood|August 12, 2011
Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use programMehdi Khellaf, Marc Michel, Philippe Quittet, et al.
Leukemia|September 15, 2025
Molecular profiling and risk stratification in solitary bone plasmacytomaBarbara Burroni, Stéphanie Harel, Raphaele Seror, et al.
Blood|September 3, 2021
Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experienceAlexis Caulier, Murielle Roussel, Pierre Morel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2019
Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple MyelomaAurore Perrot, Valérie Lauwers-Cances, Elodie Tournay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2016
Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST TrialCyrille Hulin, Andrew Belch, Chaim Shustik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2013
The translocation t(4;14) can be present only in minor subclones in multiple myelomaBenjamin Hébraud, Denis Caillot, Jill Corre, et al.
Pageof 11